$ News

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

Quanterix: Hard To Make A Good Diagnosis

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

Akoya: Q1 Earnings Snapshot

Akoya Biosciences Reports First Quarter 2025 Financial Results

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?

Quanterix, Akoya Biosciences Amend Merger Deal

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

Quanterix: Still Many, Many Questions

Q4 2024 Quanterix Corp Earnings Call

Quanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

Akoya: Q4 Earnings Snapshot

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger